SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 35.42+0.1%Dec 1 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (845)2/27/2001 1:29:31 AM
From: scaram(o)uche   of 1475
 
>> We await your post-listening opinion. <<

Not bad!

I'm mellowing a bit on Eligix. Had a good conversation with a friend who is close to this stuff today. Pointed out that the BMT registry says that 18,000 procedures are performed each year for B cell malignancies. It's still a question, of course, if 4 logs of purification will be enough. But..... I'm surprised at how many procedures are done for this indication, and I eat my earlier words.

Not difficult, at all, to see how they arrived at a figure of $150M for the EXISTING market.

And, regarding my second point...... that a little donor T cell contamination helps to condition the host.... I was referring to studies where there was global T cell depletion of donor marrow. The Eligix procedure removes only CD8-positive cells. So..... guess it would be a good idea to wait for data before popping mouth off?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News